Announcement PDF 1 29 September 2026 COHORT 1 COMPLETES DOSING AND FOLLOW-UP RLS-2202 PHASE 1A CLINICAL TRIAL HIGHLIGHTS • All Cohort 1 participants have completed dosing and the required follow-up period in the Phase 1a clinical trial of RLS-2202. • The study is designed to evaluate safety, tolerability and pharmacokinetics, and generate the data required to inform dose selection and the next stage of clinical development. • Independent Safety Review Committee meeting scheduled for October ahead of potential progression to Cohort 2, with final participant dosing remaining targeted for Q4 CY2026. Patrys Limited (ASX: PAB) (Patrys, or the Company) is pleased to announce that all participants (n=4) in Cohort 1 have completed dosing and the required follow-up period of the Phase 1a clinical trial of RLS-2202 in healthy volunteers. All Cohort 1 participants have therefore completed their planned clinical assessments. The available safety, tolerability and pharmacokinetic data from Cohort 1 will now be compiled and reviewed by the Safety Review Committee (“SRC”). The SRC is scheduled to meet in October 2026 to review the Cohort 1 data and make a recommendation regarding the dose for Cohort 2 (n=12 participants) and whether any modifications to the dosing regimen or study conduct are required. The Company cautions that, although all Cohort 1 participants have completed the planned study assessments, the formal SRC review remains outstanding. No decision regarding progression to Cohort 2 has yet been made. Subject to the SRC’s review and recommendation, the Company expects to provide a further update regarding progression to Cohort 2 during Q4 CY2026. CEO, Dr Samantha South, said: “We are pleased that Cohort 1 is now complete and would like to thank the participants and clinical teams involved. The available Cohort 1 data will now be reviewed by the Safety Review Committee and we look forward to providing a further update following the SRC meeting.” (Click here to view this announcement in the Patrys InvestorHub) Study Overview The Phase 1a is a two cohort, two period (IV:oral crossover design) study, with 16 participants in total, designed to evaluate safety, tolerability and pharmacokinetics, and generate the data required to inform dose selection and the next stage of clinical development. The study is being conducted at CMAX in Adelaide under the oversight of Alithia Life Sciences, following appropriate HREC approval and TGA acknowledgement. 2 Next Steps Following completion of Cohort 1, the key upcoming milestones for the RLS-2202 Phase 1a study are: • October 2026: The independent Safety Review Committee is scheduled to review the available Cohort 1 safety, tolerability and pharmacokinetic data in October prior to progression to Cohort 2. • Q4 CY26: Subject to a satisfactory safety review and successful quality control testing and release of the Cohort 2 clinical material, Patrys expects to commence dosing of Cohort 2. • Q4 CY26: Subject to the above, Patrys continues to target completion of dosing of the final participant in Cohort 2. Patrys intends to provide further updates as key clinical milestones are achieved and data from the study become available. -Ends- This announcement is authorised for release by the Board of Directors of Patrys Limited. For further information, please contact: General enquiries Dr Samantha South Chief Executive Officer P: + 61 421 117 241 info@patrys.com Registered Office Address 168 Stirling Highway Nedlands WA, 6009 About Patrys Limited Patrys (ASX:PAB) is a clinical-stage company developing an injectable therapy for delirium alongside a differentiated deoxymab platform targeting immune-mediated inflammatory diseases. More information can be found at www.patrys.com. Forward Looking Statements This announcement may contain certain “forward-looking statements”. Forward looking statements can generally be identified by the use of forward-looking words such as, “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.